ARNA Arena Pharmaceuticals, Inc.

1.45
+0  (1%)
Previous Close 1.43
Open 1.43
Price To book 8.72
Market Cap 355.93M
Shares 245,469,000
Volume 1,469,568
Short Ratio 6.32
Av. Daily Volume 1,787,260

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2 to be initiated 2017.
APD371
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data due by the end of 2017.
Etrasimod
Ulcerative colitis
Phase 2 data due mid-2017.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer
  3. ARENA PHARMACEUTICALS INC Financials
  4. Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
  5. How to Trade Wednesday's Most Active Stocks: Lloyds, Arena Pharma, MSCI and More
  6. Why Arena Pharmaceuticals Stock Is Surging Higher Today
  7. Wednesday’s Biggest Biopharma Movers
  8. Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
  9. 7 Most Popular Diet Pills That Work Fast Without Exercise
  10. Biotech Premarket Movers: Arena, Immunomedics, Aralez
  11. ARENA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  12. Edited Transcript of ARNA earnings conference call or presentation 14-Mar-17 8:30pm GMT
  13. Arena Pharmaceuticals beats 4Q profit forecasts
  14. Arena Pharmaceuticals beats 4Q profit forecasts
  15. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  16. Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
  17. Q4 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
  18. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 13, 2017
  19. 10 Best Performing Weight Loss Companies And Their Programs
  20. Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference